We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

173 hedge funds and large institutions have $209M invested in Revance Therapeutics, Inc. in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 42 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more call options, than puts

Call options by funds: $1.57M | Put options by funds: $775K

50% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less funds holding

Funds holding: 188 → 173 (-15)

34% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 41

49% less capital invested

Capital invested by funds: $411M → $209M (-$202M)

Holders
173
Holders Change
-15
Holders Change %
-7.98%
% of All Funds
2.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
63
Reduced
42
Closed
41
Calls
$1.57M
Puts
$775K
Net Calls
+$797K
Net Calls Change
-$1.25M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.28M
2
SCM
Stonepine Capital Management
Oregon
+$2.81M
3
N
Nuveen
North Carolina
+$2.4M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$2.3M
5
Millennium Management
Millennium Management
New York
+$2.06M

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$10.2M
2
CIBC Asset Management
CIBC Asset Management
Ontario, Canada
-$8.56M
3
SCM
Suvretta Capital Management
New York
-$5.26M
4
OM
Opaleye Management
Massachusetts
-$3.86M
5
Marshall Wace
Marshall Wace
United Kingdom
-$3.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
HighTower Advisors
26
HighTower Advisors
Illinois
$1.38M +$307K +90,000 +20%
EAM
27
EULAV Asset Management
Florida
$1.28M – – –
IHAM
28
Integral Health Asset Management
New York
$1.28M +$1.71M +500,000 New
EWM
29
Essex Woodlands Management
Texas
$1.17M – – –
ECM
30
ExodusPoint Capital Management
New York
$1.14M +$1.51M +441,584 New
GCM
31
Graham Capital Management
Connecticut
$1.07M +$1.42M +417,161 New
CM
32
CM Management
Florida
$1.03M +$512K +150,000 +60%
TCM
33
Tang Capital Management
California
$1.03M +$683K +200,000 +100%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$959K +$234K +68,451 +22%
UOC
35
UBS O'Connor
Illinois
$836K +$241K +70,647 +28%
LG
36
Lane Generational
Massachusetts
$821K +$1.09M +319,322 New
William Blair & Company
37
William Blair & Company
Illinois
$747K -$132K -38,752 -12%
DA
38
DCF Advisers
Connecticut
$643K -$45.7K -13,372 -5%
MCM
39
Moore Capital Management
New York
$643K – – –
Citadel Advisors
40
Citadel Advisors
Florida
$640K +$677K +198,366 +392%
AA
41
AlphaCentric Advisors
Puerto Rico
$630K – – –
UBS AM
42
UBS AM
Illinois
$611K +$404K +118,429 +99%
GTC
43
Ghost Tree Capital
New York
$578K -$768K -225,000 -50%
AQR Capital Management
44
AQR Capital Management
Connecticut
$517K +$584K +170,960 +568%
Assenagon Asset Management
45
Assenagon Asset Management
Luxembourg
$511K – – –
PP
46
PDT Partners
New York
$506K +$673K +197,049 New
Swiss National Bank
47
Swiss National Bank
Switzerland
$500K – – –
SSA
48
Schonfeld Strategic Advisors
New York
$498K +$661K +193,591 New
Bank of America
49
Bank of America
North Carolina
$462K -$1.11M -324,725 -64%
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$455K +$195K +57,064 +48%
1
2
3 4 5

RVNC Hedge Fund Activity: Q2 2024 in Review

173 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2024, worth a combined $209M — down 49% from $411M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of RVNC and 27 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 63 added.

The largest buyer was BlackRock, adding an estimated $4.28M. The largest seller was Barclays, cutting an estimated $10.2M.

  • 173 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2024, down from 188 in Q1 2024.
  • Funds reported $209M of Revance Therapeutics, Inc. stock for Q2 2024, down 49% quarter-over-quarter.
  • 27 funds opened new Revance Therapeutics, Inc. positions in Q2 2024 and 41 closed out, a net change of -14 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q2 2024 was BlackRock, an estimated $4.28M added.
  • The largest Revance Therapeutics, Inc. seller in Q2 2024 was Barclays, an estimated $10.2M sold.

Based on aggregated 13F filings for Q2 2024.